Tag: R&D
Construction, infrastructure issues in Russia’s auto sector
Since 2022, Western automakers left Russia, opening doors for Chinese manufacturers with SPIC incentives
Overstepping the mark
The requirement to submit a test licence in the drugs and cosmetics rules goes beyond the ambit of the Parent Act, and is a hindrance to R&D for pharma companies, writes Syngene International's Shreekanth Katti






















